Esperion Partner HLS Therapeutics Announces Approval of NILEMDO(R) for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
(NasdaqGM:ESPR),(TSX:HLS), ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company's partner in Canada for the development and commercialization of NILEMDO(R) (bempedoic acid) and NEXLIZET(R) (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol […]